SERPINF1

(redirected from PEDF)
Also found in: Acronyms.

SERPINF1

A gene on chromosome 17p13.3 that encodes a member of the serine protease inhibitor (serpin) family. SERPINF1 does not undergo the S (stressed) to R (relaxed) conformational transition characteristic of active serpins; it has no serine protease inhibitory activity, but it inhibits angiogenesis and is a neurotrophic factor involved in neuronal differentiation in retinoblastoma cells.
Mentioned in ?
References in periodicals archive ?
In this study, 72 rats undergoing optic nerve injury were randomly assigned to 3 groups: group with injections of phosphate buffered saline (PBS) (n=24), group with weekly injections of PEDF (n=24), and group with NSC-based administration of PEDF (n=24).
226) This legislation, PEDF argued, limits funds to
Blood was drawn from the antecubital vein in the morning to determine PEDF and blood chemistries.
The company combines its patented gene transfer technologies with proprietary the>rapeutic genes to create product candidates, such as BIOBYPASS angiogen and GENSTENT biologic that address medical needs in the areas of cardiovascular disease, TNFerade biologic for oncology and the PEDF program for ophthalmology.
PEDF services are not limited to offering credit, but include small business training, startup assistance, referral services, field consulting, business environment analysis, walk-in services, the creation of business plans, and microfinance.
When PEDF is released into the bloodstream, it causes the muscle and liver to become desensitised to insulin.
Triamcinolone acetonide down-regulates VEGF and ICAM-1, inhibits inflammatory cells, stabilizes cell membranes, and increases PEDF levels.
Rick King, GenVec's Senior Vice President of Research, stated, "A key objective of this grant is to expand our understanding of how PEDF influences blood vessel growth in the eye.
Our studies reported today demonstrated delivery of PEDF, a potent factor capable of both blocking and reversing animal models of AMD.
Previous animal studies have shown the potential benefits of increasing PEDF expression in the eye to prevent the growth of blood vessels (angiogenesis) that leads to vision loss.
Each of our gene-based product candidates uses a common patent-protected platform to deliver genes that produce medically beneficial proteins directly at the site of disease - TNFerade(TM) for oncology, BIOBYPASS(R) for cardiovascular disease, and PEDF for ophthalmology.
Each of our gene-based product candidates uses a common patent-protected platform to deliver genes that produce medically beneficial proteins directly at the site of disease -- TNFerade(TM) for oncology, BIOBYPASS(R) for cardiovascular disease, and PEDF for ophthalmology.